Rethinking global access to vaccines

BMJ

Volumn 336, Issue 7647, 2008, Pages 750-753

  Chokshi, Dave A ^a   Kesselheim, Aaron S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; VACCINE; WART VIRUS VACCINE;

ARTICLE; DIARRHEA; DISEASE ASSOCIATION; FUNDING; HUMAN; LOWEST INCOME GROUP; NON PROFIT ORGANIZATION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS; WORLD HEALTH ORGANIZATION;

EID: 41949130962     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39497.598044.be     Document Type: Article

References (42)

1. World Health Organization. World health report 2005: make every mother and child count. Geneva: WHO, 2005. www.who.int/whr/2005/en/index.html.
2. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006;12:304-6.
3. World Health Organization. Revised global burden of disease: 2002 estimates. Geneva: WHO, 2004. www.who.int/healthinfo/bodgbd2002revised/en/ index.html.
4. Birn AE. Gates's grandest challenge: transcending technology as public health ideology. Lancet 2005;366:514-9.
5. Major efforts for disease eradication. In: Knobler S, Lederberg J, Pray L, eds. Considerations for viral disease eradication: lessons learned and future strategies. Washington, DC: Institute of Medicine, 2002:33-63. http://books.nap.edu/openbook.php?record_ id=10424&page=33.
6. Sen AK. Development as freedom. New York: Knopf, 1999.
7. Clemens JD. Thinking downstream to accelerate the introduction of new vaccines for developing countries. Vaccine 2003;21(suppl 2):S114-5.
8. Peny JM, Gleizes O, Covilard JP. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Vaccine 2005;23:4610-8.
9. Kim S-Y, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccine in low-income countries. Bull World Health Organ 2007;85:821-900.
10. Bloom DE, Canning D, Weston M. The value of vaccination. World Economics 2005;6(3):25.
11. Brooke S, Sherris J. HPV vaccines: regulatory issues. London: PATH, 2006. www.rho.org/files/StopCxCa_regulatory_2006.pdf.
12. Cohen J. Medicine. Rethinking a vaccine's risk. Science 2001;293:1576-7.
13. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries-key challenges and issues. N Engl J Med 2007;356:1908-10.
14. Médecins Sans Frontières. Gilead's Tenofovir "access program" for developing countries: a case of false promises? February 2006.www.doctorswithoutborders.org/news/hiv-aids/ tenofovir_briefing_doc.cfm.
15. Outterson K, Kesselheim AS. Putting patients first: a market-based licensing proposal for HPV vaccines and other patented medical products in developing countries. Health Affairs 2008;27:130-9.
16. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
17. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
18. WHO position paper on rotavirus vaccines. World Health Organ Weekly Epidemiol Record 2007;82:285-96.
19. Aaby P, Samb B, Simondon F, Knudsen K, Seek AM, Bennett J, et al. Sex-specific differences in mortality after high-titre measles immunization in rural Senegal. Bull World Health Organ 1994;72:761-70.
20. Basu S, Andrews J, Smith-Rohrberg D. Populations who test drugs should benefit from them. Nature 2006;440:605.
21. The Hib Initiative. Serum Institute of India obtains first ever Indian license for its Hib vaccine developed through technology transfer from the Netherlands Vaccine Institute. 2007.www.hibaction.org/news/2007/05-03.php.
22. Meningitis Vaccine Project. Improved meningitis vaccine for Africa could signal eventual end to deadly scourge. 2007. www.meningvax.org/files/press-0706- improved-phase2.html.
23. Milstien JB, Kaddar M, Kieny MP. The impact of globalization on vaccine development and availability. Health Aff (Millwood) 2006;25:1061-9.
24. GAVI External Stakeholder Advisory Board Meeting. Global vaccine supply: the changing role of suppliers. 24 June 2005. www.gavialliance.org/ resources/BCG_24_June.pdf.
25. Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, et al. Health innovation networks to help developing countries address neglected diseases. Science 2005;309:401-4.
26. Salicrup LA, Fedorkova L. Challenges and opportunities for enhancing biotechnology and technology transfer in developing countries. Biotechnol Adv 2006;24:69-79.
27. Chokshi DA, Rajkumar R. Leveraging university research to advance global health. JAMA 2007;298:1934-6.
28. Sekhri N. Forecasting for global health: new money, new products, and new markets. 2006. www.cgdev.org/doc/ghprn/Forecasting_Background.pdf.
29. Clemens J, Jodar L. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat Med 2005;11(suppl 4):S12-5.
30. GAVI Alliance. Accelerated development and introduction of priority new vaccines (ADIPs). 2007. www.gavialiiance.org/vision/policies/new_vaccines/adips/ index.php.
31. PATH. Cervical Cancer vaccine project. 2006.www.path.org/files/ RH_cc_vacc_proj_fs_update.pdf.
32. Sanders D, Haines A. Implementation research is needed to achieve international health goals. PLoS Med 2006;3:e186.
33. Madon T, Hofman KJ, Kupfer L, Glass RI. Public health. Implementation science. Science 2007;318:1728-9.
34. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38(suppl 5):S429-36.
35. Farmer P, Kim JY. Community based approaches to the control of multidrug resistanttuberculosis: introducing "DOTS-plus." BMJ 1998;317:671-4.
36. Alliance for Health Policy and Systems Research. Strengthening health systems in developing countries: the promise of research on policy and systems. Geneva: AHPSR, 2004.
37. Buekens P, Keusch G, Belizan J, Bhutta ZA. Evidence-based global health. JAMA 2004;291:2639-41.
38. Mahmoud A. The global vaccination gap. Science 2004;305:147.
39. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
40. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
41. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-72.
42. Rotavirus vaccine program: a PATH affiliate. 2007. www.rotavirusvaccine. org/index.htm.